AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
A phase 3 trial of Ivonescimab, Carboplatin, Tislelizumab in non-small-cell lung cancer and small-cell lung cancer, run by Akeso, active and no longer recruiting.
Overview
AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT05840016 by Akeso, with 532 participants enrolled, started 2023-08-17 and due to reach its primary completion in 2025-02-28. Interventions recorded: AK112, Carboplatin, Paxlitaxel, Tislelizumab, Carboplatin, Paxlitaxel. Conditions listed: Advanced Squamous Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer
Shares Ivonescimab, Akeso, Carboplatin, Small-cell lung cancer.
- TrialAK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC
Shares Ivonescimab, Akeso, Carboplatin, Small-cell lung cancer.
- TrialIvonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer
Shares Ivonescimab, Akeso, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemor
Shares Ivonescimab, Akeso, Small-cell lung cancer.
- TrialAK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer
Shares Ivonescimab, Akeso, Carboplatin, Small-cell lung cancer.
- TrialA Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer
Shares Ivonescimab, Akeso, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPhase III Study of AK112 for NSCLC Patients
Shares Ivonescimab, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPhase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Adva
Shares Tislelizumab, Small-cell lung cancer, Non-small-cell lung cancer.